7 completed, 2 terminated, 2 unknown, 1 recruiting. 12 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Terminated 2, Unknown 2, Recruiting 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Blepharospasm: new trials by email Literature Review of Blepharospasm trials Research Report on Blepharospasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DaxibotulinumtoxinA for Blepharospasm Botulinum Neurotoxin Type A - Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2026-09-24 | 2026-09-29 |
| Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post Refractive Surgery and Associated With Blepharospasm Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops - Dry Eye Disease | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 12 | 2023-03-01 | 2023-02-22 |
| Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Dipraglurant, Placebo - Blepharospasm, Dystonia | Phase 2 | Completed | Addex Pharma S.A. | 15 | 2021-10-06 | 2025-10-03 |
| Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Cannabidiol Oral Solution [Epidiolex] - Blepharospasm, Blepharospasm, Benign Essential | Phase 2 / Phase 3 | Completed | Silkiss Eye Surgery | 12 | 2020-05-20 | 2021-11-02 |
| Wumeiwan Jiawei Fang Use in Patients With Blepharospasm Wumeiwan Jiawei Fang, botulinum toxin A - Dry Eye Syndromes, Meige Syndrome | Phase 2 / Phase 3 | Unknown | China Academy of Chinese Medical Sciences | 80 | 2018-01-12 | 2022-11-17 |
| Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Clostridium Botulinum Toxin Type A - Blepharospasm | Phase 2 / Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 234 | 2016-10-01 | 2019-06-26 |
| Acetyl Hexapeptide-8 for Blepharospasm Topical acetyl hexapeptide-8, Placebo - Focal Dystonia | Phase 2 | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 8 | 2012-11-01 | 2016-11-10 |
| A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm Acetyl-Hexapeptide Topical Treatment, placebo - Focal Dystonia | Phase 1 / Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 2009-07-01 | 2012-09-06 |
| Blepharospasm Short Interval NT 201 - Blepharospasm | Phase 2 | Terminated | Merz Pharmaceuticals GmbH | 8 | 2007-08-01 | 2012-02-06 |
| Brain Stimulation to Treat Blepharospasm or Meige Syndrome repetitive transcranial magnetic stimulation (rTMS) - Blepharospasm, Focal Dystonia | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 22 | 2006-06-22 | 2017-07-02 |
| Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm Botulinum toxin type A - Blepharospasm | Phase 2 | Completed | Ipsen | 120 | 2003-01-01 | 2019-07-29 |
| Mexiletine for the Treatment of Focal Dystonia Mexiletine - Blepharospasm, Dystonia | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 1998-07-01 | 2008-03-04 |
Dystonia (6) · Dystonic Disorders (4) · Benign essential blepharospasm (2) · Dry Eye Syndromes (2) · Spasm (2) · Meige Syndrome (1) · Parkinsonian Disorders (1)
Eye Diseases (12) · Eyelid Diseases (12) · Nervous System Diseases (7) · Neurologic Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Central Nervous System Diseases (6) · Dyskinesias (6) · Movement Disorders (6) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Lacrimal Apparatus Diseases (2) · Neuromuscular Manifestations (2) · Dystonic Disorders (1)
Botulinum Toxins, Type A (5) · 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine (1) · Cannabidiol (1) · Mexiletine (1) · Ophthalmic Solutions (1) · Transcranial Magnetic Stimulation (1) · abobotulinumtoxinA (1) · acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide (1) · incobotulinumtoxinA (1)
National Institute of Neurological Disorders and Stroke (NINDS) (4) · Addex Pharma S.A. (1) · China Academy of Chinese Medical Sciences (1) · Daewoong Pharmaceutical Co. LTD. (1) · Ipsen (1) · Merz Pharmaceuticals GmbH (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Silkiss Eye Surgery (1) · University of Pennsylvania (1)
United States (8) · China (2) · Germany (1) · South Korea (1)
Bettina Wabbels, MD (1) · Codrin I Lungu, M.D. (1) · Juan Ye, Doc. (1)